Back

Predictive factors and baseline risk stratification for CAR-T cell therapy-related cardiovascular toxicity

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Refining risk scores in cardio-oncology Cardio-Oncology ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Assistant Professor Dimitrios T Farmakis

National & Kapodistrian University of Athens, Athens (Greece)

5 More presentations in this session

Presentation thumbnail
Key immune related genes and potential therapeutic targets in immune checkpoint inhibitor associated myocarditis: a new fing
Doctor J. Zhang (Suzhou, CN)
Abstract Slides Video
Presentation thumbnail
Efficacy and safety of prolonged edoxaban treatment for gastrointestinal cancer patients with isolated distal deep vein thrombosis: insight from the ONCO DVT study
Doctor Y. Yamashita (Kyoto, JP)
Abstract Slides Video
Presentation thumbnail
Cardiovascular disease is a significant contributor to the incidence of cancer, second-primary cancer, and cancer-related hospitalization
Mr T. Caller (Tel Aviv, IL)
Abstract Slides Video
Presentation thumbnail
A novel machine learning-based adverse cardiovascular events risk score for cancer patients treated with immune checkpoint inhibitors
Mr J. Cross (New Haven, US)
Abstract Slides Video
Presentation thumbnail
Myocardial fibrosis identification in patients with anthracycline-induced cardiotoxicity: a biomarkers and cardiac magnetic resonance correlation
Doctor R. Maragna (Milan, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Refining risk scores in cardio-oncology
Video

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Cardiovascular magnetic resonance vs. echocardiography for assessing baseline cardiovascular reserve in patients undergoing CAR-T therapy
thumbnail
Congress Presentation
Patients with non-Hodgkin's lymphoma treated with CAR T-cell therapy are at risk of impaired left ventricular function
thumbnail
Congress Presentation
Low cardiovascular event rates in patients treated with CAR T-cells: real-world outcomes from two independent cohorts

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources